Yi Wang

Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF.

P. Ponikowski, G. Filippatos, G. Felker, 2018, International journal of cardiology.

Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX‐AHF trial

P. Ponikowski, G. Filippatos, M. Metra, 2017, American heart journal.

Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure

R. D. de Boer, J. Núñez, D. Keefe, 2020, British journal of clinical pharmacology.

Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.

S. Solomon, M. Pfeffer, G. Filippatos, 2021, Circulation.

A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial

P. Ponikowski, G. Filippatos, G. Felker, 2017, European journal of heart failure.

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

S. Solomon, M. Pfeffer, J. McMurray, 2021, European journal of heart failure.

Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI

M. Pfeffer, J. McMurray, C. Granger, 2023, Journal of the American Heart Association.